Aytu BioPharma Inc. (NASDAQ:AYTU) Receives $9.33 Consensus Price Target from Analysts

Aytu BioPharma Inc. (NASDAQ:AYTU) has earned an average recommendation of “Hold” from the five brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $9.3333.

Several equities analysts recently weighed in on the stock. Zacks Research upgraded shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Wednesday, April 8th. Finally, Wall Street Zen upgraded shares of Aytu BioPharma to a “hold” rating in a research report on Saturday, February 7th.

Hedge Funds Weigh In On Aytu BioPharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AYTU. Persistent Asset Partners Ltd bought a new position in shares of Aytu BioPharma in the third quarter valued at approximately $117,000. Dimensional Fund Advisors LP bought a new position in shares of Aytu BioPharma in the third quarter valued at approximately $58,000. Two Sigma Investments LP boosted its position in shares of Aytu BioPharma by 96.2% in the third quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock valued at $129,000 after acquiring an additional 33,701 shares during the period. FNY Investment Advisers LLC boosted its position in shares of Aytu BioPharma by 24,207.7% in the fourth quarter. FNY Investment Advisers LLC now owns 31,600 shares of the company’s stock valued at $82,000 after acquiring an additional 31,470 shares during the period. Finally, Daytona Street Capital LLC bought a new position in shares of Aytu BioPharma in the fourth quarter valued at approximately $26,000. Institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Stock Performance

Shares of AYTU stock opened at $2.10 on Wednesday. The firm has a market capitalization of $22.53 million, a PE ratio of -0.46 and a beta of 0.24. The firm has a fifty day simple moving average of $2.47 and a two-hundred day simple moving average of $2.45. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 0.27. Aytu BioPharma has a 12 month low of $1.46 and a 12 month high of $3.07.

Aytu BioPharma (NASDAQ:AYTU) last posted its earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.09). Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%.The firm had revenue of $12.41 million during the quarter, compared to the consensus estimate of $12.05 million. Analysts forecast that Aytu BioPharma will post -0.69 EPS for the current fiscal year.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.